Post-earnings recap
Reported
Wed, Aug 5, 2009
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 1.89% decline in stock price. The lack of revenue data and forward guidance adds uncertainty for investors. The management's cautious tone suggests that the company is focusing on its ongoing projects without clear expectations for the near future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.55 | N/A | -16.28% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance. They emphasized the importance of their ongoing projects but did not offer specific guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing projects and their potential impact.